It’s easy to get caught up in technology wars—Python versus Java versus NextBigLanguage—but the hardest part of AI isn’t the tools, it’s the people. Domain knowledge, skills, and adoption matter more ...

The reason a rescued bird refuses to leave her cage has broken hearts on TikTok, earning over 186,000 views. The clip shared by Cailin (@caitlin_and_friends) shows a yellow-collared macaw—a small, ...

Excavated with colonial labor and shipped to the Netherlands, the famous fossil is being repatriated to Indonesia along with 28,000 other fossils. The skull cap of 'Java Man' was discovered by Eugène ...

Nothing has finally rolled out Nothing OS 4 Open Beta for Nothing Phone 3a series and here’s everything it offers. Nothing OS 4 Open Beta for Nothing Phone 3a series has been released about three ...

Rajesh started following the latest happenings in the world of Android around the release of the Nexus One and Samsung Galaxy S. After flashing custom ROMs and kernels on his beloved Galaxy S, he ...

Xiaomi has greatly improved its software update policy in recent years. It had long offered a maximum of three Android OS updates to its devices, which extended to four in late 2023, starting with the ...

I spend a lot of time talking about two-factor authentication. Often I wonder if people have a real sense of its usefulness. Yeah, it helps keep hackers out of your accounts if your password somehow ...

Stable One UI 8 Watch, based on Wear OS 6, is rolling out to Galaxy Watch 7 units in Korea. The update is available for Watch 7 users who had previously enrolled in the One UI 8 Watch beta. A wider ...

Gilead Sciences and Arcus Biosciences’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of close to 27 months, keeping alive one of the last remaining hopes for this ...

BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS) in patients with prostate cancer at high risk for biochemical recurrence, ...

Even after Merck & Co.’s Keytruda has climbed to the top of the industry’s sales charts and racked up dozens of FDA-approved indications, the drug is showing it still has unfinished business. In the ...